ada standards of care 2025 obesity pharmacotherapy glp-1 recommendations Nutritional priorities to support GLP‐1 therapy for obesity: A joint Advisory from the American College Lifestyle Medicine, the American Society for Nutrition, the Medicine Association, and The Obesity Society GLP-1 Agonists Weight Loss Drugs

In 2016, concerns regarding retinopathy associated with GLP-1 were first raised in the Semaglutide Unabated Sustainability in Treatment of T2DM (SUSTAIN) 6 trial with semaglutide [89]

Proper titration, starting low and increasing gradually, is the single most important factor in tolerability across all three options

Watsons program focuses on more than just pounds lostits about restoring balance and confidence

a Nutritional recommendations and counseling are important to support weight reduction, prevent and mitigate gastrointestinal side effects, reduce muscle and bone loss, and support long-term weight maintenance